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INTRODUCTION

DISCUSSION

•	Primary angiitis of the CNS (PACNS) is a rare vasculitis that is particularly
challenging to diagnose.

•	Most patients with PACNS demonstrate improvement in symptoms and on imaging
when trialed on steroids with or without Cytoxan.

•	It should be considered in the setting of recurrent strokes, continued cognitive
decline, and recurrent or progressive focal neurological deficits.

•	No studies suggest an optimal treatment regimen or duration.

•	It is essentially a diagnosis of exclusion after ruling out systemic involvement with
1
confirmatory cerebrovascular imaging or histopathological evidence of vasculitis.
•	Current treatment recommendations include high dose corticosteroids and
cyclophosphamide. Limited data supports the use of rituximab in refractory cases of
2,3
PACNS.

•	Three case reports in the current literature describe clinical and radiographic
2,3
improvement in adults with PACNS after treatment with rituximab.
•	In one case where the diagnosis was made by angiographic findings and an
2
abnormal CSF, rituximab was given as first-line therapy.
•	In the other two cases, the diagnosis of PACNS was histopathological with evidence
of a lymphocytic vasculitic process involving the brain and spinal cord. Rituximab
2
was used as first-line in one and after failing Cytoxan in the other.
•	Our patient was deemed to have failed Cytoxan and unfortunately Rituxan.

CASE
•	Our patient is a 56-year-old male with recurrent multifocal cerebral infarcts,
encephalopathy and seizures secondary to PACNS diagnosed a year prior with
cerebral arteriogram.
•	He presented with worsening right sided weakness, expressive aphasia, and urinary
incontinence.
•	MRI upon admission revealed new areas of acute/subacute infarctions in the basal
ganglia and corona radiata.
•	Lumbar puncture was unremarkable. Other labs confirmed no underlying systemic
vasculitis with negative ANA and ANCA profiles. Renal biopsy showed diabetic
nephropathy without signs of connective tissue disease.
•	Cerebral arteriogram was repeated, showing multiple small peripheral arterial
narrowing and beading consistent with a diagnosis of PACNS.
•	Despite increasing IV corticosteroids and treatment with Cytoxan for over 6 months,
our patient continued to demonstrate decline.
•	During the hospital course, Rituxan infusions were initiated and patient began to
show clinical improvement over the following 6 weeks. He unfortunately regressed
after a few months of treatment.

•	This case shows the difficulty of diagnosing PACNS. The goal standard for the
diagnosis of PACNS is a brain biopsy.
•	Only a positive biopsy can ascertain the diagnosis which we did not have. Staining,
immunohistochemistry studies, and immunophenotyping are needed to rule out other
mimickers.
•	Refractory cases are rare and require reconsidering the diagnosis.
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